Sign up to save your podcasts
Or
Share A Conversation with William Soliman
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
A Conversation with William Soliman
Catching up on another fascinating episode—this time with Dr. Will Soliman, a pharmaceutical industry futurist, former Big Pharma executive, and founder of the Accreditation Council for Medical Affairs (ACMA). From teaching and working as a food scientist at Mars Chocolate to leading the global gold-standard certification body for pharma professionals, Dr. Soliman walks us through an unexpected journey shaped by curiosity, chance, and a life-changing relationship.
Today, he’s not only training the professionals who interact with healthcare providers—he’s also running White Mana Capital, a biotech-focused hedge fund, and advising Congress on the future of pharmaceutical standards. In this episode, Dr. Soliman opens up about the evolution of the industry, the rise of biotech, and why AI is about to reshape medicine faster than most people realize.
In this episode, you’ll learn:
• How a dating relationship unexpectedly launched Dr. Soliman into the pharmaceutical world
• What it was like transitioning from scientist to pharma executive to industry leader
• Why professional standards matter more than ever in a post-AI, rapidly evolving life-sciences landscape
• The pivotal moment he testified before Congress on the future of pharmaceutical practices
• How AI, organoids, and emerging tech are merging biology and computing in ways that will transform medicine
• Why the biotech–technology crossover is accelerating—and what it means for the future of healthcare
View all episodes
By Michael PeresCatching up on another fascinating episode—this time with Dr. Will Soliman, a pharmaceutical industry futurist, former Big Pharma executive, and founder of the Accreditation Council for Medical Affairs (ACMA). From teaching and working as a food scientist at Mars Chocolate to leading the global gold-standard certification body for pharma professionals, Dr. Soliman walks us through an unexpected journey shaped by curiosity, chance, and a life-changing relationship.
Today, he’s not only training the professionals who interact with healthcare providers—he’s also running White Mana Capital, a biotech-focused hedge fund, and advising Congress on the future of pharmaceutical standards. In this episode, Dr. Soliman opens up about the evolution of the industry, the rise of biotech, and why AI is about to reshape medicine faster than most people realize.
In this episode, you’ll learn:
• How a dating relationship unexpectedly launched Dr. Soliman into the pharmaceutical world
• What it was like transitioning from scientist to pharma executive to industry leader
• Why professional standards matter more than ever in a post-AI, rapidly evolving life-sciences landscape
• The pivotal moment he testified before Congress on the future of pharmaceutical practices
• How AI, organoids, and emerging tech are merging biology and computing in ways that will transform medicine
• Why the biotech–technology crossover is accelerating—and what it means for the future of healthcare